Publications by authors named "Tilo Senger"

Claim this Profile
D
Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling).
Fahad N Almajhdi, Tilo Senger, Haitham M Amer, Lutz Gissmann, Peter Öhlschläger

PLoS One· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients.
Maria R Gaiser, Sonja Textor, Tilo Senger, Lysann Schädlich, Tim Waterboer

J Dermatol Sci· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.
Tilo Senger, Lysann Schädlich, Sonja Textor, Corinna Klein, Kristina M Michael

Vaccine· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses.
Tilo Senger, Maria R Becker, Lysann Schädlich, Tim Waterboer, Lutz Gissmann

J Virol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity.
Lysann Schädlich, Tilo Senger, Britta Gerlach, Norbert Mücke, Corinna Klein

J Virol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced papillomavirus-like particle production in insect cells.
Tilo Senger, Lysann Schädlich, Lutz Gissmann, Martin Müller

Virology· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.
Lysann Schädlich, Tilo Senger, Carsten J Kirschning, Martin Müller, Lutz Gissmann

Vaccine· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
Bärbel Schröfelbauer, Tilo Senger, Gerard Manning, Nathaniel R Landau

J Virol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis